10
Oct
• CTIBIOTECH has been selected by SATT AxLR and CILCARE to develop the OrgaEar project, a disruptive innovation in hearing disorders research.
• Hearing disorders are a growing public health crisis. The development of innovative therapeutic solutions is an urgent strategic priority.
• Facilitating a highly advanced non-animal New Approach Methods NAMs alternative in the hearing disorders sector, CTIBIOTECH strengthens its position at the forefront of a cell-based bioassay market estimated at 28 billion euros by 2028, CAGR > 7%).
Montpellier and Lyon, France – October 9, 2025: Cilcare is...